The invention described herein is directed to compositions and methods for inducing red blood cell (RBC) differentiation. Additionally, provided herein are methods of treating a subject in need thereof by administering the induced RBC described herein.

The present application relates to the administration of plasma, fractions thereof, or mixtures thereof to humans or animals to treat or otherwise improve cognitive impairment disorders, including dementia (e.g., vascular dementia, dementia with Lewy bodies, dementia resulting from Alzheimer's disease, dementia resulting from Parkinson's disease, frontotemporal dementia, and dementia resulting from normal pressure hydrocephalus in humans, and cognitive dysfunction syndrome in companion animals), concussion, and traumatic brain injury. In certain embodiments, the invention comprises a method of treating a cognitive impairment disorder in a human or companion animal subject, said method comprising: administering to said subject one or more cognitive functioning tests to identify a subject suffering from a cognitive impairment disorder; and administering to said subject a therapeutically effective amount of an animal plasma composition; wherein said administration provides an improvement in said subject's results in said one or more cognitive impairment tests.

The present application relates to the administration of plasma, fractions thereof, or mixtures thereof to humans or animals to treat or otherwise improve cognitive impairment disorders, including dementia (e.g., vascular dementia, dementia with Lewy bodies, dementia resulting from Alzheimer's disease, dementia resulting from Parkinson's disease, frontotemporal dementia, and dementia resulting from normal pressure hydrocephalus in humans, and cognitive dysfunction syndrome in companion animals), concussion, and traumatic brain injury. In certain embodiments, the invention comprises a method of treating a cognitive impairment disorder in a human or companion animal subject, said method comprising: administering to said subject one or more cognitive functioning tests to identify a subject suffering from a cognitive impairment disorder; and administering to said subject a therapeutically effective amount of an animal plasma composition; wherein said administration provides an improvement in said subject's results in said one or more cognitive impairment tests.

An oral pharmabiotic system is disclosed for improving oral, dental, and systemic health by repopulating and reshaping the flora within a patient's oral environment in a manner that overcomes the deficiencies of prior oral probiotic products. By formulating the pharmabiotic system as a strip for adhesive placement within a patients' oral cavity, preferably against the buccal mucosa, alveolar mucosa, oral labial mucosa, or a dental appliance, and configuring the parameters of the strip such that neither disadhesion nor complete dissolution occurs for at least a period of at least three hours during daytime use and at least six hours during nighttime use, the probiotic payload contained within may remain in the oral cavity for a sufficient length of time required for the probiotics to activate, replicate, and displace existing harmful oral pathobiotics.

An oral pharmabiotic system is disclosed for improving oral, dental, and systemic health by repopulating and reshaping the flora within a patient's oral environment in a manner that overcomes the deficiencies of prior oral probiotic products. By formulating the pharmabiotic system as a strip for adhesive placement within a patients' oral cavity, preferably against the buccal mucosa, alveolar mucosa, oral labial mucosa, or a dental appliance, and configuring the parameters of the strip such that neither disadhesion nor complete dissolution occurs for at least a period of at least three hours during daytime use and at least six hours during nighttime use, the probiotic payload contained within may remain in the oral cavity for a sufficient length of time required for the probiotics to activate, replicate, and displace existing harmful oral pathobiotics.

A microcapsule and a preparation method thereof, especially a multi-layer microcapsule containing an active substance and a preparation method thereof, the microcapsule having a single-layer or a multiple-layer encapsulation structure. A probiotic microcapsule and a preparation method thereof, the probiotic microcapsule having a single-layer or a multi-layer encapsulation structure. A food product or a health product containing a probiotic microcapsule (comprising a dairy product, a fermented-style food product, a beverage, chocolate, candy, a baked good, a fruit or vegetable juice product, etc. containing a probiotic microcapsule) and a preparation method thereof. A probiotic microcapsule soft powder and a preparation method thereof, the probiotic microcapsule soft powder comprising probiotic microcapsule nata de coco soft powder and probiotic microcapsule gel ball soft powder.

A microcapsule and a preparation method thereof, especially a multi-layer microcapsule containing an active substance and a preparation method thereof, the microcapsule having a single-layer or a multiple-layer encapsulation structure. A probiotic microcapsule and a preparation method thereof, the probiotic microcapsule having a single-layer or a multi-layer encapsulation structure. A food product or a health product containing a probiotic microcapsule (comprising a dairy product, a fermented-style food product, a beverage, chocolate, candy, a baked good, a fruit or vegetable juice product, etc. containing a probiotic microcapsule) and a preparation method thereof. A probiotic microcapsule soft powder and a preparation method thereof, the probiotic microcapsule soft powder comprising probiotic microcapsule nata de coco soft powder and probiotic microcapsule gel ball soft powder.

The present disclosure provides use of transferrin, a transferrin receptor and an antibody thereof in the preparation of an anti-SARS-CoV-2 drug. Use of the transferrin, the transferrin receptor or the transferrin receptor antibody in the preparation of an anti-SARS-CoV-2 drug is provided. Both surface plasmon resonance (SPR) and immunofluorescence confirm that the SARS-CoV-2 binds to the transferrin receptor through SARS-CoV-2 spike protein; the transferrin and/or the transferrin receptor antibody competitively bind(s) to the transferrin receptor of the body, or the transferrin receptor competitively binds to a site of the SARS-CoV-2 to inhibit binding of the SARS-CoV-2 to the transferrin receptor of the body; thus, the opportunity that the SARS-CoV-2 infects cells is blocked, and the antiviral effect of the body is realized. Use of the transferrin, the transferrin receptor and the antibody thereof in the preparation of a SARS-CoV-2 spike protein-binding biological product is provided

The present disclosure provides use of transferrin, a transferrin receptor and an antibody thereof in the preparation of an anti-SARS-CoV-2 drug. Use of the transferrin, the transferrin receptor or the transferrin receptor antibody in the preparation of an anti-SARS-CoV-2 drug is provided. Both surface plasmon resonance (SPR) and immunofluorescence confirm that the SARS-CoV-2 binds to the transferrin receptor through SARS-CoV-2 spike protein; the transferrin and/or the transferrin receptor antibody competitively bind(s) to the transferrin receptor of the body, or the transferrin receptor competitively binds to a site of the SARS-CoV-2 to inhibit binding of the SARS-CoV-2 to the transferrin receptor of the body; thus, the opportunity that the SARS-CoV-2 infects cells is blocked, and the antiviral effect of the body is realized. Use of the transferrin, the transferrin receptor and the antibody thereof in the preparation of a SARS-CoV-2 spike protein-binding biological product is provided

The present invention provides a lactoferrin, a derived peptide thereof, a composition comprising the same and a use thereof for inhibiting and/or alleviating lipid synthesis. The lactoferrin comprises the amino acid sequence of SEQ ID NO: 01, and the derived peptide of the lactoferrin comprises at least one selected from the amino acid sequences of SEQ ID NO: 02, SEQ ID NO: 03, and SEQ ID NO: 04.